Jefferies Cuts Price Target on ResMed (RMD) to $56 Following 1Q Miss

October 26, 2016 7:11 AM EDT
Get Alerts RMD Hot Sheet
Price: $62.90 -0.62%

Rating Summary:
    6 Buy, 8 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 6 | Down: 10 | New: 6
Trade RMD Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies maintained an Underperform rating on ResMed (NYSE: RMD), and cut the price target to $56.00 (from $58.00), following the company's 1Q earnings report. ResMed reported a $10mn revenue miss on a $0.02 EPS miss. Organic growth of 3% drove EPS growth of 7%; however, excluding the benefit of a lower tax rate, $1.3mn in one-time gains, and $0.06 from Brightree, underlying EPS declined 9% from last year. Philips reported high-single digit category growth while Resmed reported +3% organic growth and +5% US growth. Underlying Sleep flow gen growth grew +4% versus +19% through last year.

Analyst Anthony Petrone commented, "RMD put up a $10mn/$0.02 miss; however, ex-Brightree, lower tax and onetime other gain underlying EPS declined 9% versus last year. Results were pressured by mask share losses and price erosion in the core Sleep market—risks we highlighted in our recent surveys and downgrade. Looking ahead, the new AirFit F20 mask launch will provide some offset but to what extent is unclear. Shares are still overvalued and we are lowering estimates and PT to $56."

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $64.13 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co, Earnings

Add Your Comment